Leads Biolabs Begins Phase III Trial of PD-L1/4-1BB Bispecific for Solid Tumors

Nanjing Leads Biolabs has been approved to begin a China Phase III trial of LBL-024, an anti-PD-L1/4-1BB bispecific antibody developed by Leads that will be tested in solid tumor cancers. The single-arm pivotal study will examine the candidate for registration and market authorization by China’s CDE. LBL-024 is a bispecific antibody containing anti-programmed death ligand-1 and anti-4-1BB antibodies. Leads said the candidate binds to PD-L1 with high affinity, blocking the PD-L1/PD-1 immunosuppressive pathway while activating the 4-1BB costimulatory pathway in the tumor microenvironment. More details....

Share this with colleagues: